TSHA — Taysha Gene Therapies, Inc. stock price, charts and financials

Latest market price

6.20

+0.42+7.27%

Overview Short InterestFilings

TSHAQT52Taysha Gene Therapies, Inc.·NASDAQ

Overview Short InterestFilings

6.20+7.27%

News

Up 7.3% — Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

STOK+7.14%$31.67 OCUL+2.26%$8.59 GENB-0.42%$14.28 AUPH+2.47%$14.93 MESO+2.28%$14.80 URGN+3.45%$39.92 TYRA+1.53%$32.53 IOVA+0.93%$4.36

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.36	Insider Own	10.77%	Shs Outstand	319.86M	Perf Week	4.33%

Market Cap	1.85B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-1.17%	Shs Float	265.14M	Perf Month	-11.49%

Enterprise Value	1.59B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	17.08%	Perf Quarter	-8.69%

Income	-94.00M	P/S	-	EPS this Y	-28.85%	Inst Trans	-	Short Ratio	14.03	Perf Half Y	28.16%

Sales	8.00M	P/B	8.72	EPS next Y	1.26%	ROA	-43.24%	Short Interest	45.29M	Perf YTD	5.09%

Book/sh	0.66	P/C	6.67	EPS next 5Y	-	ROE	-56.07%	52W High	7.83 -20.82%	Perf Year	111.72%

Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	-	ROIC	-47.30%	52W Low	2.72 127.56%	Perf 3Y	822.59%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	49.38% -	Gross Margin	88.22%	Volatility	6.29% 7.11%	Perf 5Y	-67.80%

Dividend TTM	-	EV/Sales	198.72	EPS Y/Y TTM	0.00%	Oper. Margin	-1774.37%	ATR (14)	0.41	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	14.04	Sales Y/Y TTM	0.00%	Profit Margin	-1738.40%	RSI (14)	47.57	Recom	2.17

Dividend Gr. 3/5Y	-	Current Ratio	14.04	EPS Q/Q	-50.00%	SMA20	-1.61%	Beta	1.24	Target Price	14.00

Payout	0.00%	Debt/Eq	0.07	Sales Q/Q	-100.00%	SMA50	-3.07%	Rel Volume	0.64	Prev Close	5.78

Employees	99	LT Debt/Eq	0.07	Earnings	Aug 11	SMA200	9.96%	Avg Volume	3.05M	Price	6.20

IPO Date	Sep 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-24.14% -	Net Debt/EBITDA	2.00	Volume	1,962,369	Change	7.27%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-21-26	Reiterated	Goldman Sachs	Buy	$11 → $13
Jun-30-26	Reiterated	Robert W. Baird		$12 → $15
Jun-23-26	Reiterated	Pivotal Research		$10 → $14
Jan-06-26	Reiterated	Raymond James		$9.00 → $13
Jan-05-26	Reiterated	Wells Fargo	Overweight	$11
Dec-04-25	Reiterated	Goldman Sachs	Neutral	$11
Dec-04-25	Reiterated	UBS		$11
Nov-14-25	Reiterated	Cantor Fitzgerald	Overweight	$13
Nov-05-25	Reiterated	JMP Securities	Market Outperform	$6.00 → $8.00
Oct-02-25	Reiterated	Robert W. Baird		$7.00 → $12

Latest News

Aug-04-26

Aug-04-2604:00PM

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11globenewswire.com

Aug-03-26

Aug-03-2608:00AM

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndromeglobenewswire.com

Jul-21-26

Jul-21-2608:43AM

Goldman Sachs Maintains Buy on Taysha Gene Therapies, Raises Price Target to $13Benzinga

Jul-02-26

Jul-02-2602:33PM

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline DataSeekingAlpha

Jun-30-26

Jun-30-2609:38AM

Taysha: 'Buy' On Interim Analysis Of TSHA-102 First Half 2027 And Broad Label Potentialseekingalpha.com

Jun-26-26

Jun-26-2602:20PM

The Disinflation Trade Has A New Address: GenomicsSeekingAlpha

Jun-25-26

Jun-25-2608:01PM

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific MeetingYahoo

04:02PM

Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific MeetingBenzinga

08:08AM

H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market SessionBenzinga

05:08AM

Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving PremarketBenzinga

02:33AM

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsYahoo

Jun-24-26

Jun-24-2605:05PM

9 Health Care Stocks Moving In Wednesday's After-Market SessionBenzinga

04:03PM

Taysha Gene Therapies Commences $200M Common Stock OfferingBenzinga

Jun-23-26

Jun-23-2601:31PM

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - SlideshowSeekingAlpha

10:45AM

BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14Benzinga

Company

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	8	10	8	15	3	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	2	0	0	0
Gross Profit	8	10	8	15	0	0	0	0
Selling, General and Administrative Excl. Other	32	34	29	30	35	41	11	0
Research and Development	66	86	66	57	91	132	32	1
Other Operating Expense	5	0	5	1	0	0	0	0
Operating Income	-94	-110	-91	-72	-126	-173	-43	-1
Interest Expense	0	0	0	5	4	1	0	0
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	1	2	2	-34	-36	0	-17	0
Net Income Before Taxes	-94	-109	-89	-112	-166	-175	-60	-1
Income Taxes	0	0	0	0	0	0	0	0
Consolidated Net Income	-94	-109	-89	-112	-166	-175	-43	-1
Net Income From Continuing Operations	-94	-109	-89	-112	-166	-175	-60	-1
Net Income	-94	-109	-89	-112	-166	-175	-43	-1
EPS (Recurring)	-0.36	-0.34	-0.36	-0.96	-3.78	-4.64	-3.40	-0.03
EPS (Basic, Before Extraordinaries)	-0.36	-0.34	-0.36	-0.96	-3.78	-4.64	-3.40	-0.03
EPS (Diluted)	-0.36	-0.34	-0.36	-0.96	-3.78	-4.64	-3.40	-0.03
EBITDA	-91	-108	-88	-105	-160	-173	-60	0
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	230.95	176.00	54.06	13.69	33.15	—	—	—
Gross Margin	100.00	100.00	100.00	100.00	0.00	—	—	—
Operating Margin	-1,175.00	-1,100.00	-1,137.50	-480.00	-4,200.00	—	—	—
Net Margin	-1,175.00	-1,090.00	-1,112.50	-746.67	-5,533.33	—	—	—
Shares Outstanding	298	320	250	116	44	38	18	37
Market Capitalization	1,848	1,760	433	205	99	443	478	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nagendran Sukumar	President and Head of R&D	Jul 10 '26	Sale	6.24	200,000	1,248,000	936,410	Jul 10
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Option Exercise	1.71	19,021	32,526	1,336,410	Apr 13
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Sale	4.46	200,000	892,000	1,136,410	Apr 13
Alam Kamran	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	4.52	1,655	7,481	1,442,131	Feb 06
Nolan Sean P.	Chief Executive Officer	Jan 26 '26	Sale	4.61	41,312	190,448	2,908,257	Jan 27
Nagendran Sukumar	President and Head of R&D	Jan 26 '26	Sale	4.61	26,918	124,092	1,317,389	Jan 27
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	4.61	23,849	109,944	1,443,786	Jan 27
Nolan Sean P.	Chief Executive Officer	Jan 23 '26	Sale	4.75	136,789	649,748	2,949,569	Jan 27
Nagendran Sukumar	President and Head of R&D	Jan 23 '26	Sale	4.75	89,132	423,377	1,344,307	Jan 27
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 23 '26	Sale	4.75	78,968	375,098	1,467,635	Jan 27
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Option Exercise	1.15	200,000	229,440	1,206,439	Jan 14
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Sale	4.71	200,000	942,000	1,006,439	Jan 14
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Option Exercise	1.71	260,047	444,680	1,266,486	Dec 01
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Sale	4.51	260,047	1,172,812	1,006,439	Dec 01
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Option Exercise	1.07	110,125	117,363	1,116,564	Dec 01

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.